The feasibility of gene therapy in the treatment of head and neck cancer

被引:4
作者
Vattemi, Emanuela [2 ]
Claudio, Pier Paolo [1 ,3 ]
机构
[1] Marshall Univ, Joan C Edwards Sch Med, Dept Biochem & Microbiol, Huntington, WV 25755 USA
[2] Univ Verona, Sect Med Oncol, Dept Clin & Expt Med, I-37126 Verona, Italy
[3] Marshall Univ, Joan C Edwards Sch Med, Dept Surg, Huntington, WV 25755 USA
关键词
SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; RECURRENT HEAD; ATTENUATED ADENOVIRUS; TUMOR-SUPPRESSOR; P53; STATUS; ONYX-015; REPLICATION; E1A; EXPRESSION;
D O I
10.1186/1758-3284-1-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Standard approach to the treatment of head and neck cancer include surgery, chemotherapy, and radiation. More recently, dramatic increases in our knowledge of the molecular and genetic basis of cancer combined with advances in technology have resulted in novel molecular therapies for this disease. In particular, gene therapy, which involves the transfer of genetic material to cells to produce a therapeutic effect, has become a promising approach. Clinical trials concerning gene therapy strategies in head and neck cancer as well as combination of these strategies with chemotherapy and radiation therapy will be discussed.
引用
收藏
页数:6
相关论文
共 32 条
  • [1] AGARVALA SS, 1998, P ASCO, V7, pA384
  • [2] [Anonymous], 2007, Drugs R D, V8, P176
  • [3] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
    Bischoff, JR
    Kim, DH
    Williams, A
    Heise, C
    Horn, S
    Muna, M
    Ng, L
    Nye, JA
    SampsonJohannes, A
    Fattaey, A
    McCormick, F
    [J]. SCIENCE, 1996, 274 (5286) : 373 - 376
  • [4] Clayman GL, 1999, CLIN CANCER RES, V5, P1715
  • [5] Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
    Clayman, GL
    El-Naggar, AK
    Lippman, SM
    Henderson, YC
    Frederick, M
    Merritt, JA
    Zumstein, LA
    Timmons, TM
    Liu, TJ
    Ginsberg, L
    Roth, JA
    Hong, WK
    Bruso, P
    Goepfert, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2221 - 2232
  • [6] Clinical highlights from the National Cancer Data Base, 1999
    Fremgen, AM
    Bland, KI
    McGinnis, LS
    Eyre, HJ
    McDonald, CJ
    Menck, HR
    Murphy, GP
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (03) : 145 - 158
  • [7] Ganly I, 2000, CLIN CANCER RES, V6, P798
  • [9] Gleich LL, 2001, ARCH OTOLARYNGOL, V127, P775
  • [10] p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
    Goodrum, FD
    Ornelles, DA
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (12) : 9479 - 9490